On May 27, Hims & Hers Health rose 5.12% in regular trading, trading at $24.86/share, with trading volume of $126 million. The rally was driven by news that company directors purchased shares during recent market weakness, signaling insider confidence in the company's valuation.

Director share purchases are widely interpreted as a positive signal, suggesting that management believes the current stock price is undervalued and holds an optimistic outlook on the company's future prospects. This move helped stabilize market sentiment and attracted buying interest following a turbulent period for the stock. Earlier this month, shares had plunged approximately 15% after the company reported a wider-than-expected Q1 net loss of $92 million and revenue of $608 million that missed analyst estimates of $617 million. Meanwhile, Bank of America lowered its price target to $25 from $28, maintaining a neutral rating, while the analyst consensus average target stands at $27.71 with an overweight rating.

Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology and primary care services. The company was founded in 2017 and is headquartered in San Francisco, CA.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)